Predict your next investment

Venture Capital
oxbio.com

See what CB Insights has to offer

Investments

267

Portfolio Exits

73

Funds

6

Partners & Customers

1

Service Providers

2

About Oxford Bioscience Partners

Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. The firm has approximately $1B of committed capital under management.

Oxford Bioscience Partners Headquarter Location

222 Berkeley Street Suite 1650

Boston, Massachusetts, 02116,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Oxford Bioscience Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Oxford Bioscience Partners in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Oxford Bioscience Partners News

Solstice Neurosciences Inc Raises 85 Million In Private Financing

Aug 2, 2017

11/9/2006 10:08:13 AM MALVERN, Pa., Nov. 8 /PRNewswire/ -- Solstice Neurosciences, Inc., a privately held biopharmaceutical company, announced that it has received a combined $85 million in Series B Equity funding and Debt financing.Highland Capital Management, L.P. of Dallas, Texas, led the Series B financing which included participation by existing Series A investors: Thomas, McNerney & Partners, Investor Growth Capital Inc., Morgan Stanley Venture Partners, and Oxford Bioscience Partners. Brett Pope and Nathan Hukill of Highland Capital Management will join Solstice's board of directors with the closing of this financing agreement. These new funds will support the company's ongoing initiatives related to movement disorders and treatment for cervical dystonia using Myobloc® (Botulinum Toxin Type B) Injectable Solution (also sold and distributed as NeuroBloc® in Europe). In addition, the proceeds from this financing will be used to fund growth initiatives and advance product development. "Solstice Neurosciences is excited to receive this new round of financial support from the investors, who recognize the value of Solstice as a growing specialty biopharmaceutical company," said Shawn O'Brien, President and Chief Executive Officer at Solstice. "Solstice is now positioned to expand MYOBLOC sales in this attractive, fast-growing, two-player neurotoxin market." Michael Pagnotta, Chief Financial Officer for Solstice, added, "Having this prominent group of investors committed to both equity funding and debt financing validates our investors' confidence and shared vision in Solstice." Aquilo Partners, Inc., a life science investment bank, was the exclusive placement agent for the equity funding. About Solstice Neurosciences, Inc.: Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. With headquarters in Malvern, Pennsylvania, Solstice has its manufacturing and customer operations in South San Francisco, California, which is supported by a nationwide sales force. Solstice's first product, Myobloc® (Botulinum Toxin Type B) Injectable Solution 5,000U/mL, represents the only botulinum toxin type B currently available to physicians and patients worldwide. Solstice purchased worldwide rights to MYOBLOC and NeuroBloc from Elan Pharmaceuticals in July 2004. MYOBLOC is sold in the United States and approved in Canada. It is also sold and distributed in 8 markets in Europe as NeuroBloc®. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. Solstice Neurosciences, Inc. has an agreement with Eisai Co., Ltd. of Tokyo, Japan, to develop and market NerBloc® (MYOBLOC) in Japan. Solstice also recently announced an agreement with DreamPharma Corporation to develop and market MYOBLOC for CD, other therapeutic and cosmetic uses in South Korea. For more information about Solstice Neurosciences, Inc., visit www.solsticeneuro.com. About Highland Capital Management, L.P. Based in Dallas, Texas, with offices in New York and London, Highland Capital Management, L.P. ("Highland Capital") is a SEC-registered investment adviser specializing in credit and alternative investment investing. Highland Capital currently manages over $30 billion in leveraged loans, high yield bonds, structured products and other assets for banks, insurance companies, pension plans, foundations, and high net worth individuals. About Cervical Dystonia Cervical Dystonia (CD), also known as spasmodic torticollis, is a condition that primarily affects the muscles of the head and neck (the cervical area of the spine). Cervical dystonia is the most common dystonia requiring referral to movement disorder clinics. While the exact cause of CD is unknown, scientists believe the problem originates in the basal ganglia area of the brain that is instrumental in movement. Dystonia has an estimated prevalence of over 300,000 cases in North America, of which 50,000 are CD patients. In general, there are three main approaches to the treatment of CD: oral medications, surgery, and neurotoxin therapy. MYOBLOC and NeuroBloc are registered trademarks of Solstice Neurosciences, Inc. NerBloc (the tradename used for MYOBLOC in Japan) is a registered trademark of Eisai Co., Ltd., Tokyo, Japan. Source: Solstice Neurosciences, Inc.

Oxford Bioscience Partners Investments

267 Investments

Oxford Bioscience Partners has made 267 investments. Their latest investment was in QurAlis as part of their Series A on May 5, 2020.

CBI Logo

Oxford Bioscience Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/13/2020

Series A

QurAlis

$42M

Yes

8

8/8/2018

Series C - II

SQZ Biotech

$72M

Yes

6

6/16/2015

Series C

Greenlight Biosciences

$20.01M

Yes

2

1/6/2015

Series D - II

Subscribe to see more

$99M

Subscribe to see more

10

11/13/2014

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/13/2020

8/8/2018

6/16/2015

1/6/2015

11/13/2014

Round

Series A

Series C - II

Series C

Series D - II

Series D

Company

QurAlis

SQZ Biotech

Greenlight Biosciences

Subscribe to see more

Subscribe to see more

Amount

$42M

$72M

$20.01M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

6

2

10

10

Oxford Bioscience Partners Portfolio Exits

73 Portfolio Exits

Oxford Bioscience Partners has 73 portfolio exits. Their latest portfolio exit was Greenlight Biosciences on February 03, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/3/2022

Reverse Merger

$99M

3

10/30/2020

IPO

$99M

Public

2

12/25/2019

IPO

$99M

Public

5

11/6/2017

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

10/3/2017

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/3/2022

10/30/2020

12/25/2019

11/6/2017

10/3/2017

Exit

Reverse Merger

IPO

IPO

Reverse Merger

Acq - P2P

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

3

2

5

10

10

Oxford Bioscience Partners Fund History

6 Fund Histories

Oxford Bioscience Partners has 6 funds, including Oxford Bioscience Partners V LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/31/2006

Oxford Bioscience Partners V LP

Early-Stage Venture Capital

Closed

$148M

1

2/6/2002

Oxford Bioscience Annex Fund

Subscribe to see more

Subscribe to see more

$99M

10

10/17/2001

Oxford Bioscience Partners IV LP

Subscribe to see more

Subscribe to see more

$99M

10

12/29/1999

Oxford Bioscience Partners III LP

Subscribe to see more

Subscribe to see more

$99M

10

4/30/1997

Oxford Bioscience Partners II LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

10/31/2006

2/6/2002

10/17/2001

12/29/1999

4/30/1997

Fund

Oxford Bioscience Partners V LP

Oxford Bioscience Annex Fund

Oxford Bioscience Partners IV LP

Oxford Bioscience Partners III LP

Oxford Bioscience Partners II LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$148M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Oxford Bioscience Partners Partners & Customers

1 Partners and customers

Oxford Bioscience Partners has 1 strategic partners and customers. Oxford Bioscience Partners recently partnered with Evotec on .

Date

Type

Business Partner

Country

News Snippet

Sources

Licensee

Germany

Evotec - Creating integrated drug discovery innovation alliances Evotec OAI to Expand Agreement with Oxford Bioscience Partners through Integration of its New Rational Drug Design Platform, EVOrational.

Hamburg , Germany | Oxfordshire , UK | Boston , USA - Evotec OAI -LRB- Deutsche Börse : EVT , TecDAX 30 -RRB- , a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries , and Oxford Bioscience Partners , Boston , USA , a premier life-sciences venture capital firm , announced today that they have expanded their 2002 agreement by integrating Evotec OAI 's newly established rational drug design platform , EVOrationale -LRB- TM -RRB- .

3

Date

Type

Licensee

Business Partner

Country

Germany

News Snippet

Evotec - Creating integrated drug discovery innovation alliances Evotec OAI to Expand Agreement with Oxford Bioscience Partners through Integration of its New Rational Drug Design Platform, EVOrational.

Hamburg , Germany | Oxfordshire , UK | Boston , USA - Evotec OAI -LRB- Deutsche Börse : EVT , TecDAX 30 -RRB- , a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries , and Oxford Bioscience Partners , Boston , USA , a premier life-sciences venture capital firm , announced today that they have expanded their 2002 agreement by integrating Evotec OAI 's newly established rational drug design platform , EVOrationale -LRB- TM -RRB- .

Sources

3

Oxford Bioscience Partners Service Providers

2 Service Providers

Oxford Bioscience Partners has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Provider Type

Counsel

Subscribe to see more

Service Type

Partnership data by VentureSource

Oxford Bioscience Partners Team

15 Team Members

Oxford Bioscience Partners has 15 team members, including current Chief Financial Officer, Raymond Charest.

Name

Work History

Title

Status

Raymond Charest

Chief Financial Officer

Current

Shari Cohen

Controller

Current

Edmund Martin Olivier

General Partner

Current

Cornelius T. Ryan

General Partner

Current

Alan G. Walton

General Partner

Current

Name

Raymond Charest

Shari Cohen

Edmund Martin Olivier

Cornelius T. Ryan

Alan G. Walton

Work History

Title

Chief Financial Officer

Controller

General Partner

General Partner

General Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.